Gene Symbol: DPM2
Full Name: Dolichol-Phosphate Mannosyltransferase Subunit 2
Chromosomal Location: 9q34.11
NCBI Gene ID: 8769
OMIM: 605143
Ensembl ID: ENSG00000110693
UniProt: O95477
The DPM2 gene encodes a regulatory subunit of the dolichol-phosphate mannose (DPM) synthase complex. DPM2 serves as a critical regulator of the DPM complex, which consists of DPM1 (catalytic subunit), DPM2 (regulatory subunit), and DPM3 (scaffold subunit). Together, these subunits catalyze the synthesis of dolichol-phosphate mannose (DPM), an essential donor substrate for protein glycosylation.
DPM2 plays several important regulatory roles:
- Complex Assembly: DPM2 is essential for proper assembly of the DPM synthase complex
- Enzyme Activity: DPM2 modulates the catalytic activity of DPM1
- Subcellular Localization: DPM2 helps localize the complex to the endoplasmic reticulum membrane
- Quality Control: DPM2 ensures proper folding and stability of the complex
The DPM synthase complex is crucial for:
- N-linked Glycosylation: Transfer of mannose to nascent polypeptides in the ER
- GPI Anchor Biosynthesis: Synthesis of glycosylphosphatidylinositol anchors
- C-mannosylation: Rare post-translational modification of tryptophan residues
¶ Protein Structure and Function
The dolichol-phosphate mannose (DPM) synthase complex consists of three subunits that work together:
- DPM1: Catalytic subunit (~40 kDa), contains the active site for mannose transfer
- DPM2: Regulatory subunit (~9 kDa), essential for complex stability and activity modulation
- DPM3: Scaffold subunit (~12 kDa), anchors the complex to the ER membrane
The DPM complex exhibits specific subunit interactions:
- DPM2-DPM3 interaction: Critical for complex assembly and ER membrane anchoring
- DPM2-DPM1 interaction: Modulates catalytic activity of DPM1
- DPM1-DPM3 interaction: Positions the catalytic site for dolichol-phosphate access
DPM2 serves multiple regulatory roles beyond complex formation:
- Enzyme kinetics: Adjusts Vmax and Km of the mannosyltransferase reaction
- Substrate channeling: Directs dolichol-phosphate to the active site
- Quality control: Ensures proper folding and prevents aggregation
- Cellular localization: Targets the complex to ER membrane microdomains
DPM2 and the glycosylation pathway are relevant to Alzheimer's disease:
- APP Glycosylation: Proper glycosylation affects amyloid precursor protein processing
- Tau Pathology: Glycosylation abnormalities in tauopathies
- Synaptic Dysfunction: Glycosylation of synaptic proteins is essential for proper synaptic function
- ER Stress: Impaired glycosylation can trigger endoplasmic reticulum stress response
- Alpha-Synuclein Modifications: Post-translational glycosylation affects alpha-synuclein aggregation
- Protein Quality Control: Glycosylation defects impact cellular protein homeostasis
- Dopaminergic Vulnerability: Glycosylation may influence neuronal susceptibility
DPM2 mutations cause Congenital Disorder of Glycosylation Type I (CDG), characterized by:
- Severe Neurological Impairment: Developmental delay, intellectual disability
- Seizures: Epileptic activity in affected individuals
- Dystonia: Movement disorders in some patients
- Systemic Manifestations: Coagulopathy, dysmorphic features
DPM2 expression is widespread:
- Central Nervous System: High expression in neurons throughout the brain
- Peripheral Tissues: Moderate expression in liver, muscle, and other organs
- Cellular Localization: Primarily endoplasmic reticulum
DPM2 is particularly important in neurons:
- High expression in pyramidal neurons of hippocampus
- Expressed in Purkinje cells of cerebellum
- Present in cortical neurons across all layers
- Critical for neuronal ER function and protein quality control
DPM2 expression is regulated by:
- ER stress: Upregulated via unfolded protein response
- Cellular energy status: AMPK-dependent modulation
- Developmental stage: Higher expression during synaptogenesis
Proper glycosylation is essential for synaptic function:
¶ Synaptic Proteins and Glycosylation
- AMPA receptors: Glycosylation affects receptor trafficking and function
- NMDA receptors: N-linked glycans modulate channel properties
- Synaptic adhesion molecules: Critical for synapse formation
- Ion channels: Glycosylation influences gating and localization
- Reduced synaptic plasticity
- Impaired learning and memory
- Altered neuronal connectivity
- Increased susceptibility to excitotoxicity
Understanding DPM2 function has therapeutic relevance:
- Enzyme replacement: Recombinant DPM complex administration
- Substrate supplementation: Dolichol-phosphate or mannose supplementation
- ** chaperone therapy**: Pharmacological chaperones to stabilize mutant DPM2
- Gene therapy: AAV-mediated DPM2 delivery to neurons
- ER stress inhibitors: Reducing cellular stress in glycosylation disorders
- UPR modulators: Targeting specific branches of unfolded protein response
- Autophagy enhancement: Clearing accumulated misfolded proteins
- APP processing: Modulating glycosylation to affect amyloid production
- Tau pathology: Glycosylation-based interventions for tauopathies
- Synaptic protection: Maintaining proper glycosylation in aging neurons
- DPM2 mutations cause autosomal recessive CDG
- Heterozygous carriers may have increased risk for certain conditions
- Gene-dosage effects are important in disease pathogenesis
| Mutation |
Effect |
Clinical Phenotype |
| c.62G>A |
p.Trp21* |
Nonsense, severe CDG |
| c.100C>T |
p.Arg34* |
Nonsense, classical CDG |
| c.178G>A |
p.Gly60Arg |
Missense, milder phenotype |
| c.220delC |
p.Leu74Cfs* |
Frameshift, severe |
DPM2 is clinically significant for:
- Newborn Screening: Some CDG types can be detected through metabolic screening
- Genetic Counseling: Family planning for at-risk couples
- Therapeutic Monitoring: Assessing treatment efficacy in glycosylation disorders
- Biomarker potential: DPM activity as a measure of glycosylation capacity